Latham & Watkins represented Mesoblast in the transaction.Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has successfully…
Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility
